Viewing data from:

ZAVZPRET

NDA

ZAVEGEPANT HYDROCHLORIDE | N216386 | PFIZER INC

1 strength1 unique patent1 unique exclusivity

Patent Timeline

1 unique patent, 1 exclusivity by expiration date

Active (1)TodayExclusivity

2027

2028

2029

2030

2031

2032

2033

2034

Today

8481546

Jun. 26, 2034

NCE

Mar. 9, 2028

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Medicare Part D Spending

CMS annual spending data for Zavzpret (2023)

Total Spending

$2.3M

Total Claims

1,847

Beneficiaries

999

Avg Cost/Unit

$194.76

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain3 active DMFs

3 active API suppliers hold Drug Master Files for this ingredient.

MOEHS IBERICA SLZAVEGEPANT

DMF 414702025

XUZHOU WANBANG JINQIAO PHARMA CO LTDZAVEGEPANT HYDROCHLORIDE

DMF 426162025

FORMOSA LABORATORIES INCZAVEGEPANT HYDROCHLORIDE

DMF 429142025

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

3 letters from Drugs@FDA

Date	Submission	Document
Aug 5, 2025	SUPPL -7	View Letter (PDF)
Mar 25, 2025	SUPPL -5	View Letter (PDF)
Mar 10, 2023	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — EQ 10MG BASE/SPRAY

RLD

1 patent1 exclusivity▴

SPRAY, METERED;NASAL | Approved: Mar 9, 2023

Patents (1)

Patent #	Expiration	PED	Drug Substance	Drug Product	Use Code	Delist
8481546	Jun 26, 2034	—	Yes	Yes		—

Exclusivities (1)

Code	Date	Status
NCE	Mar 9, 2028	Active